SCHEMBL6520992

SCHEMBL6520992

O=c1[nH]c2ncccc2c2cc(Nc3cccnc3)ccc12

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AURKA O14965 6/20 0.59
PARP1 P09874 4/20 0.59
PARP14 Q460N5 1/20 0.45
KIF11 P52732 1/20 0.43
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
METAP2 P50579 1/20 0.42
PNP P00491 1/20 0.41
AURKB Q96GD4 2/20 0.40
RAD52 P43351 1/20 0.40
KMT2A Q03164 1/20 0.40
TLR4 O00206 1/20 0.40
TLR2 O60603 1/20 0.40
MAPT P10636 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6517435 0.89 AURKA (0.67) AURKAPARP1KDM4EAURKBMAPT
SCHEMBL6525364 0.84 AURKA (0.56) AURKAPARP1KDM4ENPC1RAB9A
SCHEMBL6527204 0.84 AURKA (0.56) AURKAPARP1KDM4EKMT2AMAPT
SCHEMBL6522968 0.84 AURKA (0.59) AURKAPARP1KDM4EAURKBKMT2A
SCHEMBL6520467 0.84 AURKA (0.59) AURKAPARP1NPC1RAB9AAURKB
SCHEMBL6526939 0.83 AURKA (0.67) AURKAPARP1KDM4EAURKBMAPT
SCHEMBL6518254 0.81 AURKA (0.52) AURKAPARP1
SCHEMBL12787024 0.81 AKR1C3 (0.54) AURKAPARP1KIF11AURKBKMT2A
SCHEMBL6521162 0.81 AURKA (0.55) AURKAPARP1PARP14NPC1RAB9A
SCHEMBL6520958 0.81 AURKA (0.55) AURKAPARP1NPC1RAB9AAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 AURKA 538/4885PARP1 1693/4885PARP14 758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.